Top Markets
#1 MowCat MowCat +776.52%
#2 龙虾 (Lobster) 龙虾 (Lobster) +81.61%
#3 Akedo Akedo +49.11%
#4 Magma Finance Magma Finance +41.92%
#5 DeXe DeXe +31.41%
#6 SIXSEVEN SIXSEVEN +29.75%
#7 Cortex Cortex +26.19%
#8 MarsCoin MarsCoin +25.84%
#9 Zignaly Zignaly +17.71%
#10 Staked ZIG Staked ZIG +17.54%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Rangering i aksjer #7949
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Aksjekurs
$3.11
Markedsverdi
$1.41B
Endring (1 dag)
-1.97%
Endring (1 år)
-57.22%
Land
CN
Handel Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Kategori

Healthcare
Inntekter for Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Staidson (Beijing) BioPharmaceuticals Co., Ltd. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Staidson (Beijing) BioPharmaceuticals Co., Ltd. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH